Direct costs of antineoplastic and supportive treatment for progressive multiple myeloma in a tax-based health system.
Brøndum RF, Vestergaard AS, Børty L, Vesteghem C, Rytter AS, Nielsen MM, Severinsen MT, Jensen P, Gregersen H, El-Galaly TC, Dybkær K, Ehlers LH, Bøgsted M, Roug AS.
Brøndum RF, et al. Among authors: vestergaard as.
Future Oncol. 2021 Sep;17(25):3331-3341. doi: 10.2217/fon-2021-0189. Epub 2021 Jun 22.
Future Oncol. 2021.
PMID: 34156281